Victor O Popoola1, Farrah Tavakoli2, Brandyn D Lau3, Matthew Lankiewicz4, Patricia Ross5, Peggy Kraus6, Dauryne Shaffer7, Deborah B Hobson8, Jonathan K Aboagye9, Norma A Farrow10, Elliott R Haut11, Michael B Streiff12. 1. Division of Acute Care Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: vpopool1@jhmi.edu. 2. School of Pharmacy, The University of Maryland Baltimore, Baltimore, MD, United States. Electronic address: ftavakoli@umaryland.edu. 3. Division of Acute Care Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Division of Health Sciences Informatics, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Health Policy and Management, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; The Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, United States. Electronic address: blau2@jhmi.edu. 4. Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD, United States. Electronic address: mlankie2@jhu.edu. 5. School of Pharmacy, The University of Maryland Baltimore, Baltimore, MD, United States; Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, United States. Electronic address: pross5@jhmi.edu. 6. Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, United States. Electronic address: pkraus2@jhmi.edu. 7. Division of Acute Care Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Nursing, The Johns Hopkins Hospital, Baltimore, MD, United States. Electronic address: dshaffe1@jhmi.edu. 8. Division of Acute Care Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; The Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, United States; Department of Nursing, The Johns Hopkins Hospital, Baltimore, MD, United States. Electronic address: dhobson1@jhmi.edu. 9. Division of Acute Care Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: jaboagy1@jhmi.edu. 10. Division of Acute Care Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: nfarrow1@jhmi.edu. 11. Division of Acute Care Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Health Policy and Management, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; The Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, United States; Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: ehaut1@jhmi.edu. 12. The Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, United States; Division of Hematology, Departments of Medicine and Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: mstreif@jhmi.edu.
Abstract
BACKGROUND: Non-administration of venous thromboembolism (VTE) prophylaxis contributes to preventable patient harm. We hypothesized that non-administration would be more common for parenteral VTE prophylaxis than oral infectious disease or cardiac prophylaxis or for treatment medications. The primary study goal was to determine if non-administration of parenteral VTE prophylaxis is more frequent than other prophylactic or treatment medications. METHODS: In this retrospective cohort study of consecutive admissions we used descriptive statistics and risk ratios (RR) to compare the number of non-administered doses of VTE prophylaxis, oral infectious disease and cardiovascular prophylaxis and treatment medications. To quantify the influence of demographic and clinical characteristics on non-administration, we estimated incidence rate ratios from Poisson regression models. RESULTS: 645 patients were admitted from July 1, 2014 through March 31, 2015. Median age was 52years (Interquartile range 43-57) and 365 (56.6%) were male. Subcutaneous VTE prophylaxis doses were not administered nearly 4-fold more frequently than oral infectious disease and cardiovascular prophylaxis (RR=3.93; 95% CI 3.36-4.59) and 3-fold more frequently than treatment medications (RR=3.06; 95% CI 2.91-3.22). Ninety percent of non-administered doses of VTE prophylaxis were refused. Risk factors for non-administration included younger age (age 18-35years), male sex, uninsured status, HIV-positivity and high VTE risk status. CONCLUSIONS: Subcutaneous VTE prophylaxis is not administered more frequently than oral infectious diseases or cardiac prophylaxis and treatment medications. These data suggest that availability of an oral medication could improve the effectiveness of VTE prophylaxis in real world settings.
BACKGROUND: Non-administration of venous thromboembolism (VTE) prophylaxis contributes to preventable patient harm. We hypothesized that non-administration would be more common for parenteral VTE prophylaxis than oral infectious disease or cardiac prophylaxis or for treatment medications. The primary study goal was to determine if non-administration of parenteral VTE prophylaxis is more frequent than other prophylactic or treatment medications. METHODS: In this retrospective cohort study of consecutive admissions we used descriptive statistics and risk ratios (RR) to compare the number of non-administered doses of VTE prophylaxis, oral infectious disease and cardiovascular prophylaxis and treatment medications. To quantify the influence of demographic and clinical characteristics on non-administration, we estimated incidence rate ratios from Poisson regression models. RESULTS: 645 patients were admitted from July 1, 2014 through March 31, 2015. Median age was 52years (Interquartile range 43-57) and 365 (56.6%) were male. Subcutaneous VTE prophylaxis doses were not administered nearly 4-fold more frequently than oral infectious disease and cardiovascular prophylaxis (RR=3.93; 95% CI 3.36-4.59) and 3-fold more frequently than treatment medications (RR=3.06; 95% CI 2.91-3.22). Ninety percent of non-administered doses of VTE prophylaxis were refused. Risk factors for non-administration included younger age (age 18-35years), male sex, uninsured status, HIV-positivity and high VTE risk status. CONCLUSIONS: Subcutaneous VTE prophylaxis is not administered more frequently than oral infectious diseases or cardiac prophylaxis and treatment medications. These data suggest that availability of an oral medication could improve the effectiveness of VTE prophylaxis in real world settings.
Authors: Holly Guy; Vicki Laskier; Mark Fisher; W Richey Neuman; Iwona Bucior; Steven Deitelzweig; Alexander T Cohen Journal: Pharmacoeconomics Date: 2019-05 Impact factor: 4.981
Authors: Oluwafemi P Owodunni; Brandyn D Lau; Michael B Streiff; Peggy S Kraus; Deborah B Hobson; Dauryne L Shaffer; Kristen L W Webster; Mujan Varasteh Kia; Christine G Holzmueller; Elliott R Haut Journal: Blood Adv Date: 2019-02-26
Authors: Christopher J Pannucci; Kory I Fleming; Thomas K Varghese; John Stringham; Lyen C Huang; T Bartley Pickron; Ann Marie Prazak; Corinne Bertolaccini; Arash Momeni Journal: Ann Surg Date: 2020-10-19 Impact factor: 12.969
Authors: Behnood Bikdeli; Mahesh V Madhavan; David Jimenez; Taylor Chuich; Isaac Dreyfus; Elissa Driggin; Caroline Der Nigoghossian; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Joseph A Caprini; Alfonso J Tafur; John R Burton; Dominic P Francese; Elizabeth Y Wang; Anna Falanga; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; P Gabriel Steg; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip Journal: J Am Coll Cardiol Date: 2020-04-17 Impact factor: 24.094